AI Summary
Alnylam posted $773.69 million quarterly sales, exceeding expectations by 21%. Amvuttra's launch for ATTR-CM is progressing exceptionally well since FDA approval. Analysts raised Alnylam's 2025 sales forecast to $3.3-$3.55 billion, above consensus. Positive analyst outlooks indicate strong market positioning and growth potential. ALNY stock rose by 1.56% to $398.36, reflecting positive market sentiment.
Sentiment Rationale
Alnylam's strong revenue growth and positive analyst revisions suggest strong future performance.
Trading Thesis
The positive sales guidance and market positioning indicate sustainable growth for years.
Market-Moving
- Alnylam posted $773.69 million quarterly sales, exceeding expectations by 21%.
- Amvuttra's launch for ATTR-CM is progressing exceptionally well since FDA approval.
- Analysts raised Alnylam's 2025 sales forecast to $3.3-$3.55 billion, above consensus.
Key Facts
- Alnylam posted $773.69 million quarterly sales, exceeding expectations by 21%.
- Amvuttra's launch for ATTR-CM is progressing exceptionally well since FDA approval.
- Analysts raised Alnylam's 2025 sales forecast to $3.3-$3.55 billion, above consensus.
- Positive analyst outlooks indicate strong market positioning and growth potential.
- ALNY stock rose by 1.56% to $398.36, reflecting positive market sentiment.
Companies Mentioned
- NVS (NVS)
- REGN (REGN)
- GSK (GSK)
Corporate Developments
The article reports significant earnings and revenue guidance, crucial for ALNY's valuation.